Comments
The Glenmark scrip will remain active as it has completed the phase I enabling preclinical development program for GBR 830 and filed a phase I clinical trial application with the Netherlands authorities. GBR 830 is the first OX40 antagonistic antibody devoid of agonistic properties to enter clinical studies. GBR 830 targets auto-reactive T cells that drive the pathology in most autoimmune diseases, including, but not limited to, illnesses such as rheumatoid arthritis and lupus.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.